Abstract: The present invention provides polypeptide variants of neuregulin-1? (NRG-1?) that have enhanced or decreased binding affinity to ErbB3 and/or ErbB4. The invention also provides methods of screening and producing polypeptide variants of NRG-1? and methods of using polypeptide variants of NRG-1? for treating diseases.

Abstract: Neuregulin peptides useful in, for example, methods and compositions comprising preventing, treating or delaying various diseases or disorders are described.

Abstract: The present invention provides certain neuregulin peptides useful in, for example, methods and compositions comprising preventing, treating or delaying various diseases or disorders.

Abstract: The present invention provides polypeptide variants of neuregulin-1? (NRG-1?) that have enhanced or decreased binding affinity to ErbB3 and/or ErbB4. The invention also provides methods of screening and producing polypeptide variants of NRG-1? and methods of using polypeptide variants of NRG-1? for treating diseases.

Abstract: Neuregulin peptides useful, for example, in methods and compositions for preventing, treating or delaying various diseases or disorders are described.

Abstract: The present invention provides polypeptide variants of neuregulin-1? (NRG-1?) that have enhanced or decreased binding affinity to ErbB3 and/or ErbB4. The invention also provides methods of screening and producing polypeptide variants of NRG-1? and methods of using polypeptide variants of NRG-1? for treating diseases.

Abstract: This invention relates to polypeptides which affect myocardial cell differentiation and organisation of cardiac muscle contractile units, assay for identifying such polypeptides, and methods for improving cardiac function by the administration of such polypeptides to patients with heart disease. In one aspect, the invention provides a therapeutic composition comprising a peptide consisting of a fragment of human neuregulin ?2 isoform containing the EGF-like domain, e.g., SEQ ID NO.:2, and a physiologically acceptable carrier, excipient or stabilizer.

Abstract: The present invention relates to neukinase, a downstream protein kinase in the neuregulin signaling pathway. In certain aspects, the present invention provides isolated neukinase-encoding nucleic acids, neukinase polypeptides, oligonucleotides that hybridize to neukinase nucleic acids, and expression vectors containing neukinase-encoding sequences. The present invention further provides isolated host cells, antibodies, transgenic non-human animals, compositions, and kits relating to neukinase. In other aspects, the present invention further provides methods of identifying predisposition to cardiac dysfunction, methods of detecting the presence of neukinase, neukinase nucleic acid, methods of screening for agents which affect neukinase activity, and methods of modulating neukinase activity.